NRP2 and lung carcinoma: As these pathways exhibit compensatory activation upon cabozantinib treatment in resistant cells [34], we investigated whether VEGFC/KDR/NRP2 knockdown elicited a decrease in FGF/YAP/TAZ/AXL expression in resistant lung cancer cells.